Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries

被引：1

作者：

Lee, C-K. ^{[1
]}

Yoo, C. ^{[2
]}

Park, S. J. ^{[3
]}

Kim, H. ^{[4
,17
]}

Korphaisarn, K. ^{[5
]}

Kim, J. W. ^{[6
,11
]}

Chen, S-C. ^{[7
]}

Kim, I. ^{[8
]}

Kim, M. ^{[9
]}

Chan, S. L. ^{[10
]}

Kim, J. W. ^{[6
,11
]}

Tai, D. W. M. ^{[12
]}

Oh, S. B. ^{[13
]}

Chen, C-T. ^{[14
]}

Bae, W. K. ^{[15
,16
]}

Kim, H. ^{[4
,17
]}

Hong, J. Y. ^{[18
]}

Choi, H. J. ^{[1
,19
]}

Chon, H. J.

Lee, M. A. ^{[20
]}

机构：

[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[3] Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[4] Ulsan Univ Hosp, Div Hematol Oncol, Dept Internal Med, Ulsan, South Korea

[5] Mahidol Univ, Fac Med, Div Med Oncol, Dept Med,Siriraj Hosp, Bangkok, Thailand

[6] Seoul Natl Univ, Internal Med, Bundang Hosp, Seongnam, South Korea

[7] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan

[8] Inje Univ, Div Oncol, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea

[9] Gangneung Asan Hosp, Med Oncol Dept, Kangnung, South Korea

[10] Chinese Univ Hong Kong, Clin Oncol Dept, Sha Tin, Sino Bldg, Hong Kong, Peoples R China

[11] Korea Univ Anam Hosp, Dept Hemato oncol, Seoul, South Korea

[12] NCCS Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[13] Pusan Natl Univ, Internal Med, Yangsan Hosp, Yangsan, South Korea

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Hsin Chu Branch, Hsinchu, Taiwan

[15] Chonnam Natl Univ, Div Hematol & Oncol, Med Sch, Hwasun, South Korea

[16] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[17] Chonnam Natl Univ Hwasun Hosp, Hwasun, South Korea

[18] Chungbuk Natl Univ Hosp, Hematol Oncol, Cheonju-si, South Korea

[19] Samsung Med Ctr SMC, Div Hematol Oncol, Seoul, South Korea

[20] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

970P

引用

页码：S603 / S603

页数：1

共 50 条

[21] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
Mohri, Kunihide
Nagai, Hidenari
Matsuda, Takahisa
Igarashi, Yoshinori
Higai, Koji
ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
[22] Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
Yang, JIwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 558 - 558
[23] Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
Yang, Jiwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
LIVER CANCER, 2024,
[24] Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States
Singal, Amit G.
Ozgurdal, Kirhan
Fan, Xiaozhou
Vassilev, Zdravko
Pan, Xiaoyun
Multani, Jasjit K.
Chen, Chi-Chang
Zhou, Zifan
He, Jing
Pisa, Federica
CANCERS, 2023, 15 (23)
[25] Combined atezolizumab and bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A single center experience
Khalil, A. A.
Abdelaziz, M. A.
El Nahas, T. I.
ANNALS OF ONCOLOGY, 2024, 35 : S1492 - S1493
[26] A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
Li, Qingqing
Su, Tong
Zhang, Xu
Pan, Yanfeng
Ma, Shengli
Zhang, Lu
Zhang, Xianqiang
Gao, Xiaojuan
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3037 - 3046
[27] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
Hwang, Sangyoun
Woo, Hyun Young
Heo, Jeong
Kim, Hyung Jun
Park, Young Joo
Yi, Kiyoun
Lee, Yu Rim
Park, Soo Young
Jang, Byoung Kuk
Chung, Woo Jin
Tak, Won Young
JOURNAL OF HEPATOLOGY, 2023, 78 : S588 - S588
[28] HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Yang, Jiwon
HEPATOLOGY, 2024, 80
[29] Atezolizumab plus Bevacizumab after first-line multikinase inhibitors for advanced hepatocellular carcinoma: The concept of "drug class change"
Saitta, Carlo
Cabibbo, Giuseppe
DIGESTIVE AND LIVER DISEASE, 2023, 55 (07) : 831 - 832
[30] Real-world Data on the Diagnosis, Treatment and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT study
Sim, Yu Ki
Chong, Ming Chuen
Gandhi, Mihir
Pokharkar, Yogesh Mahadev
Zhu, Yanan
Shi, Luming
Lequn, Li
Chen, Chien-Hung
Kudo, Masatoshi
Lee, Joon Hyeok
Strasser, Simone, I
Chanwat, Rawisak
Chow, Pierce K. H.
LIVER CANCER, 2024, 13 (03) : 306 - 321

← 1 2 3 4 5 →